ARTICLE | Clinical News
Sodium zirconium cyclosilicate: Phase III data
September 29, 2014 7:00 AM UTC
Top-line data from the double-blind portion of the international Phase III HARMONIZE (ZS004) trial in 258 patients with hyperkalemia showed that once-daily 5, 10 and 15 g oral ZS-9 each met the primar...